Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Hutchmed (china) Limited LSE:HCM London Ordinary Share KYG4672N1198 ORD USD0.10
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -15.00 -2.59% 565.00 565.00 568.00 588.00 561.00 585.00 374,090 16:20:29
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 166.7 -138.8 -13.2 - 4,207

Hutchmed (china) Share Discussion Threads

Showing 3401 to 3423 of 3425 messages
Chat Pages: 137  136  135  134  133  132  131  130  129  128  127  126  Older
DateSubjectAuthorDiscuss
26/7/2021
16:07
I've done it before for the AIM and NASDAQ but the Broker currency charges make it almost impossible to get a decent return
nerdofsteel
26/7/2021
13:34
Surely there must be a smart trader somewhere who can arbitrage an almost 10% difference between HK and UK Aim?
dbadvn
26/7/2021
10:01
Results Update this week on 28th so we will see this week. 12 noon Uk time
chester9
26/7/2021
09:14
Is the last RNS going to be a drag on the recent good momentum? Looks like it could be. Shame, we were doing so much better. Long term I am sure we will still do better. Can't keep going up.
lauders
26/7/2021
09:12
625 equivalent close in HK.Prompting,no doubt,the AIM trading books to have a bid price 10% lower at 565p.Childlike rather than insightful.
steeplejack
23/7/2021
15:24
Fri, 23rd Jul 2021 12:01RNS Number : 3134GHutchmed (China) Limited23 July 2021 Stabilizing Actions and End of Stabilization Period in connection with the Global Offering Hong Kong, Shanghai & Florham Park, NJ - Friday, July 23, 2021: HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM: HCM; HKEX: 13) announces that the stabilization period in connection with the Global Offering ended on July 23, 2021, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering on June 23, 2021. The stabilizing actions undertaken by Morgan Stanley Asia Limited, as the Stabilizing Manager (or any person acting for it) during the stabilization period were: (1) over-allocations of an aggregate of 15,600,000 Offer Shares in the International Offering, representing approximately 15% of the total number of the Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option; (2) borrowing of an aggregate of 15,600,000 Shares by Morgan Stanley & Co. International plc (an affiliate of Morgan Stanley Asia Limited) from Hutchison Healthcare Holdings Limited (an indirect wholly-owned subsidiary of CK Hutchison Holdings Limited) pursuant to the Stock Borrowing Agreement dated June 23, 2021, to cover over-allocations in the International Offering; and (3) the full exercise of the Over-allotment Option by the Joint Global Coordinators, on behalf of the International Underwriters, on July 12, 2021, in respect of an aggregate of 15,600,000 Offer Shares, representing approximately 15% of the total number of the Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option, at the Offer Price, to facilitate the return to Hutchison Healthcare Holdings Limited of all the borrowed Shares under the Stock Borrowing Agreement which were used to cover over-allocations in the International Offering. There has been no purchase or sale of any Shares on the market for the purpose of price stabilization by the Stabilizing Manager during the stabilization period.
chester9
23/7/2021
08:58
Agree with your assessments. I am assuming there will be some ‘pressure̵7; on the LT holders to sell, perhaps until the results day which is on 28/7. Having seen the cornerstone investors putting huge sums into this company during the recent weeks and months, I too feel like staying here for bit longer.
sportii
23/7/2021
08:21
indeed. This will be a $20bn+ Company by 2025 in my opinion and will generate lots of cash.
nerdofsteel
22/7/2021
18:14
HM cashed up through to cash break even and will be flooded with cash over the next 2-3 years That's why the bigger investors came on board ( and HK listing of course ). These guys are looking for 2-3 times their original investment over 3 - 5 years and they do their homework. So I'm staying along for the ride. Now a 14 bagger for me ....!!!
dbadvn
22/7/2021
17:45
Will continue to be a long-term hold. I'm nearing retirement so my portfolio has become quite low risk - by my standards, anyway. I've lost a couple of hundred thousand over the years on crazy high-risk stocks. At the age of 60 I've finally realised that greed is the enemy, slow and steady rises in companies with sound fundamentals are the answer. I feel Chi-med is one of these, just a bit concerned about anti-Chinese sentiment spilling over into the markets.
nahoon
22/7/2021
13:20
Nice, you tempted to sell? Dare I say it but longer term chart looks good to me for a run to 750p. Fingers crossed.
its the oxman
22/7/2021
09:45
Anyone got any near term price insights here, went to 650p briefly on its initial spike after HK listing. So kind of expect it to revisit that as a minimum given more positive momentum now.
its the oxman
21/7/2021
08:32
Yes,having been through the rapids,i won’t be chopping out my canoe now that we appear to be in such benign waters.Will simply enjoy the ride. Back in the late 90’s my architect brother in law held a reasonable quantity of Apple shares,around £25,000 worth.(Used the Apple graphics technology in his business).He sold his shares for a goodly profit but reflects to this day that if he’d simply held on,his holding would now be worth a short £3m.Thereagain,many a tale relates opposite experiences as we know from the tech boom 20 years back.Stockmarket investment is incapable of delivering nirvana.
steeplejack
21/7/2021
08:19
Could have been worse steeplejack. Just think what you would be saying if you sold up completely? Things are look much better since the HK listing and the future will no doubt be bright for the patient! I plan to just hold what I have now for years to come and see the story, as well as share price, improve. What's the betting both will not be reality?
lauders
21/7/2021
08:16
I think that it was Jim Slater who proffered that you should leave ten per cent for the other man.It was a widely used maxim of the 1970s.I would suggest that sellers here of late (of which i'm one)have potentially ceded a great deal more than ten per cent!......but hey ho,we're not fortune tellers just fortune hunters.HK equiv currently 620p
steeplejack
20/7/2021
11:19
So, Never wrong to take a profit.
dbadvn
20/7/2021
09:36
606p HK equivalent close.Yes,i sold some stock a pound lower and am now forced to ponder buying back in.Sometimes its best just to ignore day to day volatility and do a Warren Buffet but where would our market operators be then!
steeplejack
19/7/2021
16:44
Ditto.....shame I sold 2/3 my holding a month ago. Stick to the day job this investment stuff is hard lol
rabiddog
19/7/2021
15:37
Just amazing to see HCM the only BLUE in a see of RED in my 53-strong list of shares I watch, - changed days indeed!
fionascott1234
18/7/2021
18:09
Yet another publication warning US investors about Chinese-listed stocks: (It's from Barrons. I don't like to infringe copyright but can't stand R Murdoch and his role in spreading fake news, so don't feel too bad about the copy and paste.) Anyway, I'm just really glad we're now listed in HK.... The giant “caution”; sign for investors who own Chinese stocks has been blinking for months. It’s about to become a blaring beacon of warning. Individual investors who still own, or are considering owning, individual shares of U.S.-listed Chinese stocks need to heed this warning. Barron’s has been writing about the challenges that face Chinese companies on multiple fronts: Beijing has steadily intensified the regulatory scrutiny of its largest technology companies, while U.S.-China tensions escalate and prompt investment restrictions and legislation that create further market ramifications. Yes, the case for investing in China is strong, especially over the long run. China’s rapid economic growth is generally appealing, and has led to a burgeoning middle class that has, in turn, allowed many nascent industries to blossom. Plus, many of China’s homegrown technology companies benefit from government investment, and U.S.-China tensions. But as Barron’s wrote earlier this month, the way to navigate this landscape is by hiring a tour guide in the form of a mutual fund or exchange-traded fund manager that can manage growing complexities. Each week makes that case even stronger. Owning individual shares of Chinese companies listed in the U.S.—whether they’re traded over the counter (rather than on a major exchange) or as American Depositary Receipts (ADRs)—could increasingly become a risky proposition. Institutional investors who have the option of owning shares on a Hong Kong or mainland China stock exchange are well on their way to that transition—which could add pressure to U.S.-listed shares and eventually cause liquidity problems. The ADR-heavy Invesco Golden Dragon exchange-traded fund (PGJ) is down 13% in the last three months. The iShares MSCI China (MCHI), which also owns Hong Kong-listed shares, is down 4%, and the iShares MSCI China A-shares (CNYA), which focuses on China-listed companies, is up 7%. The latest cloud looming over U.S.-listed Chinese companies is uncertainty around how U.S. regulators will enforce last year’s Holding Foreign Companies Accountable Act, which requires foreign companies to adhere to U.S. auditing standards in order to trade on U.S. exchanges. The Chinese government has long prevented Chinese companies from providing the necessary information to comply with U.S. auditing requirements. The process toward enforcement is underway; the feedback period for a Public Company Accounting Oversight Board (PCAOB) proposal closes this week, and policy watchers expect a rule to be released soon. A PCAOB spokeswoman declined to comment. The rule will pave the way for the Securities and Exchange Commission to enforce the legislation. Currently there is a three year-window for compliance; the Senate last month passed a bill that would accelerate the timeline to just two years—another indication of the bipartisan support for China measures. Despite policy makers’ urgency, policy watchers note a lot of outstanding questions. There are some 248 Chinese companies listed on U.S. exchanges with a combined market value of more than $2 trillion—so the process of delisting could be messy and painful. “If a delisting is imminent, the stock price is going to plummet and those who control the company can buy out public investors for a bargain, go private, and relist in Asia at a much higher valuation and make a ton of money—at Americans’ expense,” says Jesse Fried, a professor at Harvard Law School who has been researching regulation of Chinese firms trading in the United States. There’s also no precedent for the type of mass delisting that could unwind in a worse-case scenario—a factor that could lead to an elusive compromise between the two nations. “Despite the ongoing, heightened tensions between the U.S. and China, this could be the last salvo bringing both sides back to the table to work out some deal where there will be just enough access to audit personnel and work papers so that the nuclear option is avoided and the PCAOB will be able to meet its core obligations under the Sarbanes-Oxley Act,” says Shas Das, counsel at King & Spalding, who was the PCAOB’s chief negotiator with Chinese regulators between 2011 and 2015. Past negotiations yielded some cooperation and access to audit work papers but not consistently, he adds. Investors would be ill-advised to wait around to see if some compromise materializes, especially as U.S.-China tensions continue to ratchet higher. On Thursday, the Senate passed a bill to ban imported products from China’s Xinjiang region amid allegations of forced-labor practices, and the U.S. has been adding Chinese companies to a blacklist, cutting them off from U.S. investment. Investors got a painful glimpse at the havoc these measures can cause when widely held China Mobile was delisted in January by the New York Stock Exchange, following an executive order from President Donald Trump banning investment in companies the U.S. said had ties to China’s military. Institutional investors were able to convert into Hong Kong-listed shares, but many retail investors have been stuck in limbo—even now, many investors cannot execute a sale at their current broker, and some are being told to seek out foreign brokers. Others have run into dead-ends with no clarity on who to reach out to for assistance, and face being stuck with a loss. The SEC didn’t respond to a request for comment.
nahoon
16/7/2021
06:18
Wonderful news today that an MAA has been submitted to the EMA for Sulanda® who have up to a maximum of 210 days to make a decision so approval could be by early 2022. It will be interesting to see what partnership/commercial deal Hutchmed get to handle the sales of Sulanda® in Europe. Https://www.ema.europa.eu/en/documents/leaflet/applying-european-union-marketing-authorisation-medicinal-products-human-use_en.pdf
nerdofsteel
15/7/2021
10:06
Would be nice, resisted temptation to sell out over 600p, still hopeful this has scope to double or triple if drug delivery goes to plan.
its the oxman
15/7/2021
09:51
563p equiv HK.The more erratic period of price performance seems to be subsiding.Hopefully,we can enjoy a steadier build from chart bottom left to top right
steeplejack
Chat Pages: 137  136  135  134  133  132  131  130  129  128  127  126  Older
ADVFN Advertorial
Your Recent History
LSE
HCM
Hutchmed (..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210727 01:50:11